Michael Shulman

Four Biotech Stocks to Play the Sector Pullback

Several of these stocks -- notably Generex -- are trading vehicles, not investment vehicles. I have followed this and several of the other companies on your list and sadly do not think they have real potential given the paucity of marketing and trial partnerships. Antigenics is a fascinating play on intellectual property and will spike if Dendreon gets an approval for Provenge or collapse.